References
- 1. Austad SN. Why women live longer than men: sex differences in longevity. Gend Med. 2006;3(2):79-92.
- 2. Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update. 20041;10(5):409-19.
- 3. Angell P, Chester N, Green D, Somauroo J, Whyte G, George K. Anabolic steroids and cardiovascular risk. Sports Med. 2012;42(2): 119-34.
- 4. Evans NA. Current concepts in anabolic-androgenic steroids. Am J Sports Med. 2004;32(2):534-42.
- 5. Pärssinen M, Kujala U, Vartiainen E, Sarna S, Seppälä T. Increased premature mortality of competitive powerlifters suspected to have used anabolic agents. Int J Sports Med. 2000;21(03):225-7.
- 6. Michels G, Hoppe UC. Rapid actions of androgens. Front Neuroendocrinol. 2008;29(2):182-98.
- 7. Vicencio JM, Estrada M, Galvis D, Bravo R, E Contreras A, Rotter D, et al. Anabolic androgenic steroids and intracellular calcium signaling: a mini review on mechanisms and physiological implications. Mini Rev Med Chem. 2011;11(5):390-8.
- 8. Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. Molecular pathways: inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res. 2013;19(13):3353-9.
- 9. Siemińska L. Tkanka tłuszczowa. Patofizjologia, rozmieszczenie, różnice płciowe oraz znaczenie w procesach zapalnych i nowotworowych. Endokrynol Pol. 2007;58(4):330-49.
- 10. Neves MA, Dinis TC, Colombo G, Sá e Melo ML. Combining computational and biochemical studies for a rationale on the anti-aromatase activity of natural polyphenols. ChemMedChem. 2007;2(12):1750-62.
- 11. Balunas MJ, Su B, Brueggemeier RW, Kinghorn AD. Natural products as aromatase inhibitors. Anticancer Agents Med Chem. 2008;8(6):646-82.
- 12. Bosco C, Colli R, Bonomi R, Von Duvillard SP, Viru A. Monitoring strength training: neuromuscular and hormonal profile. Med Sci Sports Exerc. 2000;32(1):202-8.
- 13. Powers ME. The safety and efficacy of anabolic steroid precursors: what is the scientific evidence? J Athl Train. 2002;37(3):300-305.
- 14. Boden WE, Probstfield JL, Anderson T et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med, 2011;365(24):2255-67.
- 15. Nimptsch K, Platz EA, Willett WC, Giovannucci E. Association between plasma 25-OH vitamin D and testosterone levels in men. Clin Endocrinol (Oxf). 2012;77(1):106-12.
- 16. Chmiel-Majewska K, Daniewska D, Misiorowski G, Zgliczyński W, Gellert R. Vitamin D, sex hormones and anaemia in men–is there an influence of cholecalciferol supplementation on haemoglobin concentrations or regulation of sex hormones in male haemodialysis patients? A pilot study. Post Nauk Med. 2015;10:688-92.
- 17. Staton A. Integrative Medicine. Rakel D. Elsevier USA: 2012;321-334.
- 18. Hunt CD, Johnson PE, Herbel J, Mullen LK. Effects of dietary zinc depletion on seminal volume and zinc loss, serum testosterone concentrations, and sperm morphology in young men. Am J Clin Nutr. 1992;56(1):148-57.
- 19. Wang C, Catlin DH, Starcevic B, Heber D, Ambler C, Berman N, et al. Low-fat high-fiber diet decreased serum and urine androgens in men. J Clin Endocrinol Metab. 2005;90(6):3550-9.
- 20. Steels E, Rao A, Vitetta L. Physiological aspects of male libido enhanced by standardized Trigonella foenum graecum extract and mineral formulation. Phytother Res. 2011;25(9):1294-300.
- 21. Shaner AA, Vingren JL, Hatfield DL, Budnar Jr RG, Duplanty AA, Hill DW. The acute hormonal response to free weight and machine weight resistance exercise. J Strength Cond Res. 2014;28(4):1032-40.
- 22. Marks LS, Mazer NA, Mostaghel E, Hess DL, Dorey FJ, Epstein JI, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA. 2006;296(19):2351-61.
- 23. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am J Psychiatry. 1996;153(8):974.
- 24. Daly RC, Su TP, Schmidt PJ, Pagliaro M, Pickar D, Rubinow DR. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology. 2003;28(3):317-31.
- 25. Henderson LP, Penatti CA, Jones BL, Yang P, Clark AS. Anabolic androgenic steroids and forebrain GABAergic transmission. Neuroscience. 2006;138(3):793-9.
- 26. Ambar G, Chiavegatto S. Anabolic-androgenic steroid treatment induces behavioral disinhibition and downregulation of serotonin receptor messenger RNA in the prefrontal cortex and amygdala of male mice. Genes Brain Behav. 2009;8(2):161-73.
- 27. Kohtz AS, Frye CA. Dissociating behavioral, autonomic, and neuroendocrine effects of androgen steroids in animal models. Methods Mol Biol. 2012;829:397-431.
- 28. Brower KJ. Anabolic steroid abuse and dependence. Phys Sportsmed. 2002;4(5):377-87.
- 29. Malone JD, Dimeff RJ, Lombardo JA, Sample RH. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin J Sport Med. 1995;5(1):25-31.
- 30. Achar S, Rostamian A, Narayan SM. Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm. Am J Cardiol. 2010;106(6):893-901.
- 31. Nieminen MS, Rämö MP, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M, et al. Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. Eur Heart J. 1996;17(10):1576-83.
- 32. Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513-54.
- 33. Applebaum-Bowden D, Haffner SM, Hazzard WR. The dyslipoproteinemia of anabolic steroid therapy: increase in hepatic triglyceride lipase precedes the decrease in high density lipoprotein 2 cholesterol. Metabolism. 1987;36(10):949-52.
- 34. Ferenchick GS. Anabolic/androgenic steroid abuse and thrombosis: is there a connection? Med Hypotheses. 1991;35(1):27-31.
- 35. Nakao J, Chang WC, Murota SI, Orimo H. Testosterone inhibits prostacyclin production by rat aortic smooth muscle cells in culture. Atherosclerosis. 1981;39(2):203-9.
- 36. Lane HA, Grace F, Smith JC, Morris K, Cockcroft J, Scanlon MF, et al. Impaired vasoreactivity in bodybuilders using androgenic anabolic steroids. Eur J Clin Invest. 2006;36(7):483-8.
- 37. Alen M. Androgenic steroid effects on liver and red cells. Br J Sports Med. 1985;19(1):15-20.
- 38. Dickerman RD, McConathy WJ, Schaller F, Zachariah NY. Cardiovascular complications and anabolic steroids. Eur Heart J. 1996;17(12):1912.
- 39. Lenders JW, Demacker PN, Vos JA, Jansen PL, Hoitsma AJ, Van’t Laar A, et al. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int J Sports Med. 1988;9(01):19-23.
- 40. Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004; 90(5):496-501.
- 41. Di Bello V, Giorgi D, Bianchi MA, et al. Effects of anabolic-androgenic steroids on weight-lifters’ myocardium: an ultrasonic videodensitometric study. Med Sci Sports Exerc. 1999;31(4):514-521.
- 42. Kuipers H, Wijnen JA, Hartgens F, Willems SM. Influence of anabolic steroids on body composition, blood pressure, lipid profile and liver functions in body builders. Int J Sports Med. 1991;12(04):413-8.
- 43. Friedl KE, Hannan Jr CJ, Jones RE, Plymate SR. High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism. 1990;39(1):69-74.
- 44. Hartgens F, Cheriex EC, Kuipers H. Prospective echocardiographic assessment of androgenic-anabolic steroids effects on cardiac structure and function in strength athletes. Int J Sports Med. 2003;24(05):344-51.
- 45. Marsh JD, Lehmann MH, Ritchie RH, Gwathmey JK, Green GE, Schiebinger RJ. Androgen receptors mediate hypertrophy in cardiac myocytes. Circulation. 1998;98(3):256-61.
- 46. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev. 2003;24(3):313-40.
- 47. Payne JR, Kotwinski PJ, Montgomery HE. Cardiac effects of anabolic steroids. Heart. 2004;90(5):473-5.
- 48. El Osta R, Almont T, Diligent C, Hubert N, Eschwège P, Hubert J. Anabolic steroids abuse and male infertility. Basic Clin Androl. 2016;26(1):2.
- 49. Pirola I, Cappelli C, Delbarba A, Scalvini T, Agosti B, Assanelli D, et al. Anabolic steroids purchased on the Internet as a cause of prolonged hypogonadotropic hypogonadism. Fertil Steril. 2010;94(6):2331-e1.
- 50. Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid–induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271-9.
- 51. de Souza GL, Hallak J. Anabolic steroids and male infertility: a comprehensive review. BJU Int. 2011;108(11):1860-5.
- 52. Nangia AK. Anabolic steroid abuse: a paradox of manliness. Fertil Steril. 2014;101(5):1247.